We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Noninvasive Procedure Improves Success Rate of IVF

By LabMedica International staff writers
Posted on 19 Nov 2008
A safe, simple, noninvasive procedure provides an objective measure of embryo viability, and when used as an adjunct to morphology, helps clinicians identify embryos of highest reproductive potential for in vitro fertilization (IVF). More...


Called the ViaMetrics-E procedure, it uses a highly sensitive method of metabolomic analysis by near infrared (NIR) spectroscopy, the can be performed on-site in just minutes, requiring only a small amount of spent culture media.

The procedure promises to be revolutionary for the millions of people worldwide who are affected by infertility. The technology fulfills an unmet medical need and it is well positioned to tap into the US$4 billion global IVF market. Further, the technology may hold significant potential to increase IVF success rates, while minimizing the number IVF cycles required to achieve a live birth. ViaMetrics-E could also provide physicians with a procedure that will reduce the incidence, costs, and medical risks associated with multiple births, which constitute more than one-third of births under current IVF methods.

ViaMetrics-E was developed by the metabolomics company, Molecular Biometrics (Chester, NJ, USA). Safeguard Scientifics (Wayne, PA, USA), a holding company that provides growth capital for entrepreneurial and innovative technology and life sciences companies, has announced it co-led a $12 million Series A financing round with Oxford Bioscience Partners (OBP; Boston, MA, USA), a venture capital firm, for Molecular Biometrics. Molecular Biometrics will use the financing to support ongoing R&D for ViaMetrics-E and to launch the patented technology in Europe, Japan, and Australia sometime in 2009.

James A. Datin, executive vice president and managing director of the Life Sciences Group at Safeguard commented, "Safeguard partners with entrepreneurial life sciences companies who have differentiated products and a competitive advantage in markets that represent sizable opportunities. We look for strong management teams that address key strategic themes throughout our target markets--molecular and point-of-care diagnostics, medical devices or specialty pharmaceuticals--and are on a solid trajectory towards global commercialization.”

Related Links:
Molecular Biometrics
Safeguard Scientifics
Oxford Bioscience Partners


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.